Results 71 to 80 of about 4,502 (202)

Aprepitant for the Prevention of Acute Chemotherapy-Induced Nausea and Vomiting in Children: Overcoming Barriers

, 2018
Aprepitant is an effective antiemetic for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) in children. This thesis presents an updated clinical practice guideline for the prevention of acute CINV that recommends children receiving
Patel, Priya
core   +1 more source

Aprepitant loaded solid preconcentrated microemulsion for enhanced bioavailability: A comparison with micronized Aprepitant

European Journal of Pharmaceutical Sciences, 2015
Aprepitant (APT) is a lipophilic, poorly water soluble drug with moderate permeability characteristic. Therefore, we aimed to improve solubility as well as permeability that could possibly improve oral bioavailability of APT. For this purpose, Quality by design (QbD) approach employing simplex lattice mixture design was used to prepare solid ...
Sunil, Kamboj, Radhika, Sharma, Kuldeep, Singh, Vikas, Rana   +3 more
openaire   +2 more sources

Managing Skin Side Effects Associated With Oncology Treatments: Asian Perspective on Use of Dermocosmetics

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 2, Page 186-198, April 2026.
Skin adverse events (AEs) frequently accompany all types of anticancer treatments. This publication discusses how recent international guidance on best‐practices use of dermocosmetics can be adapted to the North Asia region (China, Hong Kong, Japan, Republic of Korea, and Taiwan).
Meng Pan, Jianguo Sun, Makoto Kawashima, You Chan Kim, Mison Chun, Chia‐Yu Chu, Yi‐Hsin Liang, Mee Chang, Delphine Kerob, Brigitte Dreno   +9 more
wiley   +1 more source

Efficacy and Safety of Conventional and Biologic Therapies in Prurigo Nodularis: A Systematic Review and Meta‐Analysis

International Journal of Dermatology, Volume 65, Issue 4, Page 724-736, April 2026.
ABSTRACT Prurigo nodularis (PN) is a chronic, intensely pruritic skin disorder characterized by hyperkeratotic nodules and a debilitating itch–scratch cycle. Conventional therapies have limited efficacy and safety issues, while biologics have recently emerged as a promising alternative.
Andrea Lancz, Fanni Adél Meznerics, Renáta Árok, Anna Sára Lengyel, Bence Szabó, Péter Hegyi, Norbert Kiss, András Bánvölgyi   +7 more
wiley   +1 more source

Can aprepitant used for nausea and vomiting be good gastrointestinal complaints?

, 2020
Aprepitant is a selective SP/NK-1 receptor antagonist and used in postoperative and chemotherapeutics induced emesis and vomiting. The aim of our study is to show aprepitant may have beneficial effects on gastrointestinal complaints in cancer patients ...
Muhammed Yayla, UĞAN, Rüstem Anıl, Yayla, Muhammed, HALICI, Zekai, Duygu Kose, Tastan, Tugba Bal, Zekai Halici, KÖSE, Duygu, Un, Harun, Rustem Anil Ugan, ÇADIRCI, Elif, Elif Cadirci, Harun Un, Tugba Bal Tastan   +13 more
core   +1 more source

Comparison of aprepitant versus ondansetron for prevention of postoperative nausea and vomiting: A systematic review and meta-analysis with trial sequential analysis

Indian Journal of Anaesthesia
Background and Aims: Postoperative nausea and vomiting (PONV) is a common complication after surgery. Preventing PONV in high-risk patients often requires a multimodal approach combining antiemetic drugs with diverse mechanisms.
Madhusudan P. Singh, Meenalotchini P. Gurunthalingam, Ayushee Gupta, Juhi Singh   +3 more
doaj   +1 more source

Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU)

Acta Dermato-Venereologica, 2019
The aim of this multicentre, randomized, double-blind, placebo-controlled, cross-over, phase-II study was to determine the antipruritic effect of aprepitant vs.
Athanasios Tsianakas, Claudia Zeidler, Claudia Riepe, Matthias Borowski, Caroline Forner, Joachim Gerss, Martin Metz, Petra Staubach, Ulrike Raap, Martin Kaatz, Marc Urban, Thomas A. Luger, Sonja Ständer   +12 more
doaj   +1 more source

Two Cases of Fatal Encephalopathy Related to Ifosfamide: An Adverse Role of Aprepitant

Case Reports in Oncology, 2014
Ifosfamide is used in the treatment of sarcomas and other tumors. It sometimes provokes encephalopathy, which is a serious complication even if it is usually reversible within 48-72 h after drug cessation.
Alice Séjourné, Sabine Noal, Mathieu Boone, Céline Bihan, Marion Sassier, Michel Andrejak, Bruno Chauffert   +6 more
doaj   +1 more source

Interindividual variations in aprepitant plasma pharmacokinetics in cancer patients receiving cisplatin-based chemotherapy for the first time [PDF]

, 2013
浜松医科大学博士（医学）doctoral医学系研究科The pharmacokinetics of aprepitant, a neurokinin-1 receptor antagonist, have not been fully evaluated in clinical settings. The aim of this study was to characterize the plasma pharmacokinetics of aprepitant and reveal their ...
Motohashi, Shinya
core   +1 more source

Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting

, 2011
INTRODUCTION: Aprepitant is the only neurokinin (NK(1)) receptor antagonist (RA) approved for prevention of chemotherapy-induced nausea and vomiting (CINV). Aprepitant is co-administered with a 5-HT(3) RA and a corticosteroid. Although aprepitant is safe,
Herrstedt, Jørn, Ruhlmann, Christina H, Jørn Herrstedt, Christina H Ruhlmann   +3 more
core   +1 more source